niclosamide / Generic mfg. - LARVOL DELTA

Establishment of an ex vivo vascular tissue model to investigate bunyavirus-triggered vascular endothelial injury. (PubMed, mBio) - "This model enables evaluation of antiviral compound efficacy, demonstrating that niclosamide or 4'-fluorouridine significantly inhibits SFTSV and RVFV replication in ex vivo vascular tissues. These findings establish the ex vivo human vascular tissue as a valuable tool for investigating bunyavirus-induced vascular pathogenesis and for evaluating antiviral therapeutics...Using this model, we demonstrate that bunyavirus infection triggers endothelial disruption and that antiviral compounds can suppress viral replication and alleviate infection-associated tissue injury. This model provides a valuable experimental system for studying virus-vascular interactions and can support antiviral development against emerging bunyaviruses."

Journal • Preclinical • Hematological Disorders • Infectious Disease • Respiratory Diseases • Thrombocytopenia

Repositioning niclosamide and alectinib to inhibit the hyperphosphorylation of SARS-CoV-2's nucleocapsid protein. (PubMed, Br J Pharmacol) - "This work provides the biochemical basis for a novel approach to treat COVID-19 by synergistically repositioning two FDA-approved drugs."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Targeted Protein Degradation

Incidental Taeniasis During Screening Colonoscopy in an Asymptomatic Urban Patient: Highlighting a Persistent Public Health Concern (ACG 2026) - "The patient also received treatment that differed from current guideline recommendations, which favor praziquantel 10 mg/kg as a single dose or niclosamide 2 g as a single dose. Familiarity with the endoscopic appearance of intestinal helminths may facilitate diagnosis and appropriate treatment. Figure: Endoscopic visualization of a tapeworm within the colonic lumen during screening colonoscopy Figure: Tapeworm identified in the terminal ileum, with clear visualization of the interproglottid segmentation"

Clinical • Colorectal Cancer • Infectious Disease • Solid Tumor

Niclosamide suppresses breast cancer progression and enhances paclitaxel sensitivity by targeting the ATP6AP1-YY1-XIAP axis. (PubMed, Acta Pharmacol Sin) - "Taken together, these findings demonstrated that ATP6AP1 promotes breast cancer progression through activation of the YY1-XIAP signaling axis. Niclosamide was also identified as a promising therapeutic agent targeting ATP6AP1, thereby providing a potential therapeutic strategy for breast cancer treatment."

Journal • Breast Cancer • Oncology • Solid Tumor • ATP6AP1 • XIAP • YY1

Penetrium Is a Novel Niclosamide-Based Therapeutic That Modulates Cancer-Associated Fibroblasts in the NSCLC Tumor Microenvironment (IASLC-WCLC 2026) - "Pathway enrichment analysis in Penetrium-treated organoids and CAF co-culture models. Conclusions : Penetrium alters the NSCLC microenvironment with CAF-selective cytotoxicity, Treg depletion, and in vivo ICI synergy collectively establishing a translationally compelling preclinical rationale for clinical investigation in NSCLC and other solid tumors."

Biomarker • IO biomarker • Tumor microenvironment • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CAFs • LY6E

S100A4 enhances the pro-fibrotic effect of macrophage to promote collagen capsule formation of Trichinella spiralis. (PubMed, PLoS Negl Trop Dis) - "In conclusion, infection with T. spiralis significantly upregulated S100A4 expression in skeletal muscle-infiltrating macrophages. S100A4 further promoted macrophage M2 polarization. The M2-like macrophages either drove fibroblast activation or acquired myofibroblast-like features, thereby fostering collagen capsule formation. Blocking S100A4 diminished macrophage M2 polarization, prevented collagen capsule formation, and represented a potential adjunctive strategy against trichinellosis."

Journal • Infectious Disease • IL4 • MRC1 • S100A4 • TGFB1

Structural Insights and Biological Activities of Salicylanilide-based Compounds: A Comprehensive Review. (PubMed, Mini Rev Med Chem) - "Collectively, the available evidence highlights the salicylanilide scaffold as a promising platform for the development of novel therapeutics. The SAR insights summarized in this review provide a valuable framework for the rational design and optimization of next-generation salicylanilide-based drug candidates and support further in vivo and clinical investigations of this scaffold."

Journal • Cardiovascular • Genetic Disorders • Obesity • Oncology

Synthesis and Biological Evaluation of Glutathione-Responsive 2-Alkoxycarbonyl Allyl Niclosamide Prodrugs as Anticancer Agents. (PubMed, Curr Med Chem) - "The studies herein provide a novel methodology for the application of BH prodrugs on the niclosamide template and anticancer applications."

Journal • Breast Cancer • Oncology • Solid Tumor

Screening of candidate antiparasitic drugs against Sparicotyle chrysophrii: A phenotypic drug discovery approach. (PubMed, Vet Parasitol) - "Among the tested compounds, three salicylanilide derivatives exhibited the highest short-term efficacy, showing the lowest lethal doses 50 (LD50): niclosamide (LD50=0.12 µM), closantel (LD50=2.3 µM), and ME1.62 (LD50=0.09 µM). Niclosamide, one of the most potent compounds identified, demonstrated a parasiticidal activity more than 11,000-times greater than praziquantel (LD50=1.43 mM), a reference chemotherapeutic agent commonly used against fish polyopisthocotylean parasites."

Journal • Infectious Disease

Optimized LC-MS/MS method for simultaneous determination of multiclass veterinary anthelmintic residues in animal-derived matrices. (PubMed, Food Sci Anim Resour) - "In Korea, maximum residue limits (MRLs) have been established to regulate such residues; however, for certain substances, including niclosamide, a widely used anthelmintic, only qualitative analytical methods are available, limiting effective residue monitoring...Furthermore, recovery rates at all target concentrations satisfied CODEX performance criteria, demonstrating acceptable accuracy and precision. The developed method can enhance the efficiency of residue analysis and provide a technical basis for establishing safety management standards for livestock and fishery products."

Journal

2-Deoxyglucose Dendrimer-Enabled Niclosamide Delivery to FRβ-Expressing Macrophages Alleviates Endometriosis Progression and Associated Hyperalgesia. (PubMed, Adv Healthc Mater) - "A single intraperitoneal dose of FA-2DG-D-Niclo (25 or 50 mg/kg/bw of niclosamide) significantly reduced FRβ+ macrophage burden, suppressed lesion number and volume, and markedly improved EuE-associated hyperalgesia at 2 weeks post-treatment. Together, these findings establish FRβ+ macrophages as a potential target in EuE and present FA-2DG-D-Niclo as a nonhormonal, macrophage-focused nanomedicine for precise and effective endometriosis treatment."

Journal • Endometriosis • Gynecology • Inflammation • Women's Health

Repurposing niclosamide ethanolamine for alveolar echinococcosis reveals a disconnect between in vitro efficacy and in vivo outcome in the intraperitoneal infection model. (PubMed, PLoS Negl Trop Dis) - "Although niclosamide and NEN demonstrated potent activity against E. multilocularis in vitro, this efficacy did not translate in the mouse model. The lack of in vivo activity could be attributed to several factors such as infection model, limited drug uptake by the parasite in the animal, or the rapid metabolization of the compound. Future studies should explore novel niclosamide derivatives and formulations to enhance efficacy against AE in vivo."

Journal • Preclinical • Infectious Disease • Oncology

ARSENIC-INDUCED ADAPTIVE REPROGRAMMING IN GASTRIC CANCER AND THERAPEUTIC TARGETING OF G9A BY NICLOSAMIDE ETHANOLAMINE (UEGW 2026) - No abstract available

Gastric Cancer • Oncology • Solid Tumor

Unlocking Niclosamide Solid Forms via Mechanochemistry: Discovery of a 2-Pyrrolidone Solvate. (PubMed, Pharmaceutics) - " Mechanochemical screening represents an efficient strategy for exploring the solvate landscape of niclosamide. The newly discovered 2-pyrrolidone solvate combines structural stability and favorable solid-state performance, highlighting its potential relevance for future pharmaceutical development."

Journal

Supramolecular Complexation of Niclosamide and Nafamostat: Improved Physicochemical Profile and Enhanced Anticancer Effect. (PubMed, Pharmaceuticals (Basel)) - "Furthermore, in vivo studies revealed a twofold increase in tumor growth inhibition and a tenfold reduction in total tumor burden (p < 0.05). These findings demonstrate that the NNC supramolecular crystalline phase platform successfully optimizes membrane permeability and antitumor efficacy, highlighting its potential for treating advanced cancers."

Journal • Oncology • Pancreatic Cancer • Solid Tumor

Multiplex PCR-supported identification of Taenia saginata following proglottid passage in a long-term expatriate resident of Bali, Indonesia: A case report. (PubMed, IDCases) - "The patient was treated with a single 2-g oral dose of niclosamide followed by magnesium sulfate...saginata should be considered in long-term residents of endemic areas who report proglottid passage, even without gastrointestinal symptoms. Molecular testing can support species-level identification when microscopy demonstrates morphologically indistinguishable Taenia eggs."

Journal • Infectious Disease

The bacterial pH gradient contributes to persistence in Mycobacterium tuberculosis. (PubMed, mBio) - "Unexpectedly, we identified a strong inducer of drug tolerance-the antiparasitic niclosamide (NCA), which is known to disrupt proton motive force...We identified three Mtb genes that contribute to either promoting or mitigating the tolerant state. These findings highlight that chemical disruption of the pH gradient is a facile and rapid way to induce drug tolerance, offering a potentially useful tool to probe persister biology in TB and other infectious diseases."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Molecular Docking and Simulation-Based Exploration of Niclosamide as a Potential Inhibitor of the p62 ZZ Domain. (PubMed, Biology (Basel)) - "These findings suggest that niclosamide may function as a stable physical "lid" over the p62 ZZ domain, occluding its N-degron-binding cleft. Taken together, our computational framework highlights niclosamide as a promising candidate for AML drug repurposing, providing a hypothesis-generating foundation that warrants rigorous experimental validation."

Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FOXM1 • SQSTM1

Dual-Layered, pH-Responsive PLGA-Based Nanocarriers for Enhanced Niclosamide Delivery and Anticancer Activity. (PubMed, ACS Appl Bio Mater) - "The presence of apoptosis in niclosamide-loaded PLGA@Na-CMC-CaCO3 nanocarriers was confirmed by the JC-1 assay, which clearly demonstrated a dose-dependent decrease in mitochondrial membrane potential in the drug encapsulated nanocarrier system. Overall, this PLGA@Na-CMC-CaCO3 nanocarrier system has the potential to effectively address the key limitations of niclosamide delivery for improved cancer therapy."

Journal • Oncology

Design, synthesis, and evaluation of anti-solid-tumor activity of niclosamide-based STAT3/HDAC dual-target inhibitors. (PubMed, Bioorg Chem) - "Docking and 100-ns molecular dynamics simulations further supported chemically plausible binding modes in the HDAC1 catalytic pocket and the STAT3 SH2 domain. Overall, these findings support niclosamide as a tractable scaffold for mechanism-driven STAT3/HDAC dual-target inhibitor design and identify NS06 as a promising lead for further optimization against solid tumors."

Journal • Oncology • Solid Tumor • HDAC11 • HDAC3 • HDAC4 • JAK1 • LIFR • STAT3

Integrative Network-Based Transcriptomic Analysis Identifies Niclosamide as a Candidate Repositioned Drug for Breast Cancer. (PubMed, Breast Cancer (Dove Med Press)) - "Drug repositioning was performed using L1000CDS2, and in vitro validation of a top drug candidate (niclosamide) and an exploratory comparative compound (amitriptyline) was performed using MCF-7 cells, including viability and combination assays. These findings remain exploratory and do not provide definitive clinical evidence. Further validation across additional models and clinical settings is required."

IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • BCL2 • CDH1 • CXCL8 • EGR1 • ER • IL6 • KRAS • PACERR • PTGS2 • RECQL4

An Open Label, Cross-Over Phase 1 Study to Determine the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of Niclosamide Under Fed and Fasted Conditions in Healthy Volunteers. (PubMed, J Clin Med) - "Administration with food substantially enhances systemic exposure and transiently achieves plasma concentrations associated with in vitro antiviral activity against Zika virus. These findings support further development of optimized niclosamide formulations to achieve sustained systemic exposure for antiviral therapeutic applications."

Journal • P1 data • PK/PD data • Infectious Disease

Niclosamide reprograms macrophages and improves muscle integrity in Duchenne muscular dystrophy models. (PubMed, Biochem Pharmacol) - "These effects were accompanied by modulation of key markers involved in muscle proliferation and differentiation, supporting a beneficial role of niclosamide in promoting muscle repair in dystrophic muscle. Overall, these findings indicate that niclosamide promotes an anti-inflammatory and pro-regenerative environment, enhancing myoblast differentiation and limiting muscle degeneration, supporting its potential role as a promising therapeutic candidate for Duchenne muscular dystrophy."

Journal • CNS Disorders • Duchenne Muscular Dystrophy • Fibrosis • Genetic Disorders • Immunology • Inflammation • Muscular Dystrophy

Phenotype-Oriented Characterization of NSC828786 Identifies Convergent HPN-AMACR-Associated Transcriptomic Signatures in Prostate Adenocarcinoma and Broad-Spectrum Antiproliferative Activity. (PubMed, Cells) - "Niclosamide and related salicylanilide compounds have emerged as multitarget anticancer agents, but the molecular contexts associated with their activity remain incompletely understood...Structure-based analyses supported computational compatibility of NSC828786 with predicted HPN- and AMACR-associated binding regions, while zebrafish assays showed no overt developmental abnormalities at concentrations ≤ 5 μM. These findings identify NSC828786 as a phenotypically active salicylanilide derivative and position HPN and AMACR as exploratory candidate molecular associations warranting further mechanistic and target engagement studies."

Journal • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • AR

Reprogramming the Tumor Oncobiosphere: Bioactive Nanohybrid Materials for Reversing Therapeutic Pseudo-Resistance. (PubMed, ACS Omega) - "Nanoengineered agents, such as nanoniclosamide (nano-NIC), and ECM-targeting delivery systems may disrupt pathological matrix remodeling and restore tissue permissiveness. By reprogramming the oncobiosphere, therapeutic resistance can be viewed as a reversible ecological state, opening avenues for more durable anticancer responses across treatment modalities."

Journal • Review • Fibrosis • Oncology • CTNNB1 • STAT3 • TGFB1